Chinese researchers say flu drug effective against COVID-19

Chinese researchers say flu drug effective against COVID-19

The flu drug favipiravir is "clearly effective" in treating patients with the novel coronavirus, Chinese researchers say.

Their trial of favipiravir included 340 patients with COVID-19 in China. Those who received the drug recovered quicker and showed greater lung improvement than those who did not get the drug, the U.K."s Daily Mail reported.

It is believed that favipiravir blocks COVID-19 from replicating in the body. Favipiravir was effective in helping COVID-19 patients recover and caused no obvious side effects, Zhang Xinmin, an official at the China Science and Technology Ministry, said at a news conference Tuesday, the Daily Mail reported. However, other suggest favipiravir does not help COVID-19 patients with more severe illness.

Favipiravir is the in a Japanese flu drug called Avigan, but it is not known if that was the drug given to the Chinese patients. Currently, there is no treatment for COVID-19. Most people develop mild symptoms and recover at home within a week, the Daily Mail reported.

COVID-19 continued its insidious spread throughout America on Tuesday, as all 50 states and the District of Columbia, Puerto Rico, Guam, and U.S. Virgin Islands reported cases, and the death toll approached 100 according to the U.S. Centers for Disease Control and Prevention.

More information: Daily Mail Article
More Information

Copyright © 2020 HealthDay. All rights reserved.

Citation: Chinese researchers say flu drug effective against COVID-19 (2020, March 19) retrieved 26 April 2024 from https://medicalxpress.com/news/2020-03-chinese-flu-drug-effective-covid-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

79 shares

Feedback to editors